Roche walks away from Repare solid tumor deal just weeks after $40M milestone payout
Roche has terminated its license agreement with Repare Therapeutics for the cancer drug camonsertib in a move described by analysts as “particularly strange” in light of a recent milestone payment.
The pharma giant decided to end the agreement effective May 7 after reviewing its pipeline and “evolving external factors,” according to a Repare release. The deal dates back to June 2022, when Repare got $125 million upfront and was eligible for up to $1.2 billion in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
